- Home
- CLMT vs JANX Comparison
CLMT vs JANX Comparison
Compare CLMT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLMT | JANX |
|---|---|---|
| Founded | 1916 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLMT | JANX |
|---|---|---|
| Price | $20.25 | $13.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $20.45 | ★ $59.18 |
| AVG Volume (30 Days) | 933.9K | ★ 2.0M |
| Earning Date | 02-27-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,048,000,000.00 | $10,000,000.00 |
| Revenue This Year | $0.23 | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.68 | $13.26 |
| 52 Week High | $22.10 | $47.58 |
Technical Indicators
Market Signals| Indicator | CLMT | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 59.10 | 32.69 |
| Support Level | $19.29 | $13.68 |
| Resistance Level | $21.27 | $14.34 |
| Average True Range (ATR) | 0.75 | 0.46 |
| MACD | 0.05 | 0.43 |
| Stochastic Oscillator | 69.79 | 33.33 |
Price Performance
Historical ComparisonAbout CLMT Calumet Specialty Products Partners L.P.
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.